Jagsonpal Pharma Announces ₹40 Crore Buyback at ₹250 Per Share; Promoters to Skip Tender Offer

Synopsis :Jagsonpal Pharmaceuticals Limited has announced a share buyback worth up to Rs. 40 crore through the tender offer route. The company plans to repurchase up to 16 lakh fully paid up equity shares at a buyback price of Rs. 250 per share. The buyback opens on May 8, 2026 and closes on May 14, 2026, while May 4, 2026 has been fixed as the record date for determining shareholder eligibility.

Jagsonpal Pharma has a total market capitalization of Rs. 1,403.88 crore, according to data on the BSE. Jagsonpal Pharmashares were trading at Rs. 208.78 apiece on the Bombay Stock Exchange; the stock has surged around 0.50 percent over the last five sessions, while it has surged about 9.42 percent  in the 30 days. Over a six month period, the stock has given a negative return of 3.36 percent , whereas on a year on year basis it has declined nearly 5.02 percent, reflecting declining overall performance. The stock’s 52 week high was Rs. 301.65 and 52 week low was Rs. 155.

Jagsonpal Pharmaceuticals Limited has announced a buyback of up to 16 lakh equity shares having a face value of Rs. 2 each at a price of Rs. 250 per share through the tender offer route. The total buyback size stands at Rs. 40 crore, excluding transaction costs and represents around 18.35 percent of the company’s paid up equity capital and free reserves as per the latest audited financial statements for FY25.

The company has fixed May 4, 2026 as the record date to determine eligible shareholders who can participate in the buyback. The buyback window will open on May 8, 2026 and close on May 14, 2026, while settlement of bids is expected to be completed by May 21, 2026.

Under the offer, Jagsonpal Pharma plans to buy back approximately 2.38 percent of its total outstanding equity shares. The company stated that the buyback will be carried out on a proportionate basis through the stock exchange mechanism in accordance with SEBI Buyback Regulations, 2018.

A key positive factor for public shareholders is that the promoters and promoter group have decided not to participate in the buyback. According to the Letter of Offer, the promoter group collectively holds around 67.71 percent stake in the company and their non participation could improve the acceptance ratio for public shareholders participating in the tender offer.

The buyback price of Rs. 250 per share generally reflects management confidence in the company’s long term business outlook and valuation. Such corporate actions often support shareholder value by reducing the number of outstanding shares, which can improve earnings per share (EPS), return ratios and overall capital efficiency over time.

The company also clarified that the buyback will be funded entirely through internal accruals, cash balances and surplus funds and not through borrowed money. This indicates relatively comfortable liquidity and balance sheet strength.

Jagsonpal Pharmaceuticals operates in the pharmaceutical sector with a focus on branded formulations and healthcare products. Over the years, the company has strengthened its portfolio across therapeutic categories and continues to expand its presence in the domestic pharmaceutical market.

For small shareholders, the company has reserved a separate entitlement category as mandated under SEBI regulations. The indicative buyback entitlement ratio stands at 47 equity shares for every 637 shares held on the record date.

Overall, Jagsonpal Pharma’s Rs. 40 crore buyback reflects a shareholder reward strategy while also aiming to improve capital structure efficiency. The actual impact on shareholders will depend on the final acceptance ratio, market price movement during the tender period and future business performance of the company.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing. 

The post Jagsonpal Pharma Announces ₹40 Crore Buyback at ₹250 Per Share; Promoters to Skip Tender Offer appeared first on Trade Brains.